TR201814710T4 - Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı - Google Patents

Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı Download PDF

Info

Publication number
TR201814710T4
TR201814710T4 TR2018/14710T TR201814710T TR201814710T4 TR 201814710 T4 TR201814710 T4 TR 201814710T4 TR 2018/14710 T TR2018/14710 T TR 2018/14710T TR 201814710 T TR201814710 T TR 201814710T TR 201814710 T4 TR201814710 T4 TR 201814710T4
Authority
TR
Turkey
Prior art keywords
pain
disease
newly developed
nasal
inflammatory
Prior art date
Application number
TR2018/14710T
Other languages
English (en)
Turkish (tr)
Inventor
Su Ho Pil
Oh Yoon Dong
Young Han Sun
Sook Kim Jung
Seong Park Woul
Oh Ahn Sung
Jung Kim Hye
Il Lee Won
Original Assignee
C&C Res Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Res Lab filed Critical C&C Res Lab
Publication of TR201814710T4 publication Critical patent/TR201814710T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TR2018/14710T 2011-09-30 2012-09-28 Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı TR201814710T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110100369 2011-09-30
KR20120033444 2012-03-30

Publications (1)

Publication Number Publication Date
TR201814710T4 true TR201814710T4 (tr) 2019-01-21

Family

ID=47996667

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/14710T TR201814710T4 (tr) 2011-09-30 2012-09-28 Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı

Country Status (26)

Country Link
US (1) US9586959B2 (cg-RX-API-DMAC10.html)
EP (2) EP3461825B1 (cg-RX-API-DMAC10.html)
JP (1) JP6031107B2 (cg-RX-API-DMAC10.html)
KR (1) KR101800749B1 (cg-RX-API-DMAC10.html)
CN (1) CN103889986B (cg-RX-API-DMAC10.html)
AR (1) AR088085A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012316912B9 (cg-RX-API-DMAC10.html)
BR (1) BR112014007645A2 (cg-RX-API-DMAC10.html)
CA (1) CA2848154C (cg-RX-API-DMAC10.html)
CY (1) CY1121292T1 (cg-RX-API-DMAC10.html)
DK (2) DK2760865T3 (cg-RX-API-DMAC10.html)
ES (2) ES2687693T3 (cg-RX-API-DMAC10.html)
FI (1) FI3461825T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20181310T1 (cg-RX-API-DMAC10.html)
HU (2) HUE062842T2 (cg-RX-API-DMAC10.html)
LT (2) LT2760865T (cg-RX-API-DMAC10.html)
MX (1) MX355795B (cg-RX-API-DMAC10.html)
PL (2) PL3461825T3 (cg-RX-API-DMAC10.html)
PT (2) PT3461825T (cg-RX-API-DMAC10.html)
RS (2) RS64575B1 (cg-RX-API-DMAC10.html)
RU (1) RU2628074C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201400484RA (cg-RX-API-DMAC10.html)
SI (2) SI3461825T1 (cg-RX-API-DMAC10.html)
TR (1) TR201814710T4 (cg-RX-API-DMAC10.html)
TW (1) TWI551600B (cg-RX-API-DMAC10.html)
WO (1) WO2013048214A2 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015000715A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN112010772A (zh) * 2016-01-26 2020-12-01 赵鸣 5-氨基酮戊酸及其衍生物的盐化合物和应用
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018111003A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2018139876A1 (ko) * 2017-01-26 2018-08-02 동화약품주식회사 신규한 [1, 2, 4] 트리아졸로 [4, 3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 bet 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
JP6876833B2 (ja) * 2017-02-27 2021-05-26 ▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司Betta Pharmaceuticals Co., Ltd. Fgfr阻害剤およびその使用
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商C&C新藥研究所 雜環衍生物及其用途
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
TW202317568A (zh) * 2021-06-22 2023-05-01 丹麥商理奧藥品公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺半琥珀酸鹽之新穎結晶形式
TW202428578A (zh) * 2022-09-29 2024-07-16 韓商Jw製藥公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺之新穎結晶型
AU2023348200A1 (en) * 2022-09-29 2025-03-27 Jw Pharmaceutical Corporation A process for the manufacture of salts and crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine and novel crystalline forms
TW202425977A (zh) * 2022-09-30 2024-07-01 韓商Jw製藥公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺單琥珀酸鹽之新穎結晶型
CN116554092B (zh) * 2023-05-18 2026-07-17 上海锐谱医药科技有限公司 一种制备新药砌块(6-甲酰基吡啶-3-基)氨基甲酸叔丁酯的方法
US12173001B1 (en) 2024-01-16 2024-12-24 King Faisal University Pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidines as CK2 inhibitors
US12122775B1 (en) 2024-01-16 2024-10-22 King Faisal University Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors
US12129252B1 (en) 2024-02-15 2024-10-29 King Faisal University Pyrrolo[2,3-c][2,6]naphthyridine-8-carboxylic acids as CK2 inhibitors
CN119732334A (zh) * 2024-11-20 2025-04-01 华中科技大学同济医学院附属同济医院 一种儿童炎症性肠病大鼠模型的构建方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
US5070086A (en) * 1987-12-23 1991-12-03 Schering Corporation Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds
CA2310072A1 (en) * 1997-11-11 1999-05-20 Hiroyuki Ohno Fused pyrazine compounds
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
JP2000319277A (ja) * 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
EP1613629A1 (en) * 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US20090143392A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
SI2268618T1 (sl) * 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
JP2012502067A (ja) 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
CN100580335C (zh) * 2008-09-11 2010-01-13 艾欧史密斯(中国)热水器有限公司 承压式太阳能热水器
ES2550101T3 (es) * 2008-12-17 2015-11-04 Merck Patent Gmbh Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
EP2389379A1 (en) 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011060207A1 (en) * 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
JP6031107B2 (ja) 2016-11-24
EP2760865A2 (en) 2014-08-06
DK2760865T3 (en) 2018-10-08
KR20140090984A (ko) 2014-07-18
RS57854B1 (sr) 2018-12-31
PL3461825T3 (pl) 2023-10-30
AU2012316912B2 (en) 2017-04-20
US9586959B2 (en) 2017-03-07
AU2012316912B9 (en) 2017-04-27
WO2013048214A3 (en) 2013-05-23
ES2954303T3 (es) 2023-11-21
ES2687693T3 (es) 2018-10-26
KR101800749B1 (ko) 2017-11-24
PT2760865T (pt) 2018-11-05
MX355795B (es) 2018-04-30
EP3461825A1 (en) 2019-04-03
WO2013048214A2 (en) 2013-04-04
SI2760865T1 (sl) 2018-10-30
HUE040374T2 (hu) 2019-03-28
JP2014531458A (ja) 2014-11-27
HRP20181310T1 (hr) 2018-10-19
LT2760865T (lt) 2018-09-25
PL2760865T3 (pl) 2018-12-31
US20140315888A1 (en) 2014-10-23
MX2014003042A (es) 2014-05-28
HRP20230893T1 (hr) 2023-11-24
TWI551600B (zh) 2016-10-01
EP2760865A4 (en) 2015-03-18
FI3461825T3 (fi) 2023-08-17
AU2012316912A1 (en) 2014-03-20
EP3461825B1 (en) 2023-06-07
AU2012316912A8 (en) 2014-04-10
RU2014115478A (ru) 2015-11-10
RS64575B1 (sr) 2023-10-31
PT3461825T (pt) 2023-09-11
CN103889986B (zh) 2017-07-21
CA2848154A1 (en) 2013-04-04
CN103889986A (zh) 2014-06-25
EP2760865B1 (en) 2018-07-11
LT3461825T (lt) 2023-08-25
SI3461825T1 (sl) 2023-11-30
CA2848154C (en) 2020-04-28
BR112014007645A2 (pt) 2017-04-18
HUE062842T2 (hu) 2023-12-28
AR088085A1 (es) 2014-05-07
CY1121292T1 (el) 2020-05-29
TW201321381A (zh) 2013-06-01
RU2628074C2 (ru) 2017-08-14
SG11201400484RA (en) 2014-10-30
DK3461825T3 (da) 2023-08-14

Similar Documents

Publication Publication Date Title
MX355795B (es) Nuevos derivados heterocíclicos y sus usos.
MX2013012983A (es) Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
IN2012CH01573A (cg-RX-API-DMAC10.html)
CL2016002888A1 (es) Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras.
UA111767C2 (uk) Дигідропіримідинізохінолінони і фармацевтичні композиції, які їх містять, для лікування запальних порушень
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
EA201490858A1 (ru) Соединения гетероарилпиридона и аза-пиридона в качестве ингибиторов тирозинкиназы брутона
SA518391624B1 (ar) Ror- منظمات جاما
MX2015010248A (es) Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios.
EA201590721A1 (ru) Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
IL221829A (en) Heterocyclic inhibitors of histamine receptors for the treatment of the disease
EA201492250A1 (ru) Гетероциклическое соединение
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
NZ720660A (en) Apoptosis signal-regulating kinase inhibitors
NZ629728A (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
MX2020011955A (es) Derivados heterociclicos y uso de los mismos.
NO20080125L (no) 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
WO2014093230A3 (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
PE20151536A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
EA201690645A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
MX2018003008A (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA202192032A1 (ru) Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение
MY181814A (en) Pyrazolothiazole compound and medicine comprising same